The activation by extracellular
nucleotides of pancreatic P2Y receptors, particularly, the P2Y(1)R subtype, increases insulin secretion. Therefore, we developed analogues of the P2Y(1)R receptor agonist
2-MeS-ADP, as potential
antidiabetic drugs. Analogue 3A was found to be a potent P2Y(1)R agonist (EC(50) = 0.038 μM vs 0.0025 μM for 2-MeS-
ADP) showing no activity at P2Y(2/4/6)Rs. Analogue 3A was stable at pH 1.4 (t(1/2) = 7.3 h) and resistant to hydrolysis vs
2-MeS-ADP by
alkaline phosphatase (t(1/2) = 6 vs 4.5 h), human e-NPP1 (4% vs 16% hydrolysis after 20 min), and human blood serum (30% vs 50% hydrolysis after 24 h).
Intravenous administration of 3A in naive rats decreased
blood glucose from 155 mg/dL to normal values, ca. 87 mg/dL, unlike
glibenclamide, leading to subnormal values (i.e., 63 mg/dL). Similar observations were made for
streptozotocin (STZ)-treated and db(+)/db(-) mouse models. Furthermore, 3A inhibits platelet aggregation in vitro and elongates bleeding time in mice (iv administration of 30 mg of 3A/kg), increasing bleeding time to 16 vs 9 min for
Prasugrel.
Oral administration of 30 mg/kg 3A to rats increased tail
bleeding volume, similar to
aspirin. These findings suggest that 3A may be an effective treatment for
type 2 diabetes by reducing both
blood glucose levels and platelet aggregation.